1. Wilne, S., et al., Presentation of childhood CNS tumours:a systematic review and meta-analysis. Lancet Oncol, 2007. 8(8): p. 685-95. 2. Taquechel, C., et al., Tumores del sistema nervioso central en la infancia. MEDISAN, 2003. 7(4): p. 30-4. 3. Packer, R., CNS tumors. 2007, SIOP Education Book 4. Jahraus, C. and N. Tarbell, Optic Pathway Gliomas. Pediatr Blood Cancer. , 2006 46(5): p. 586-96. 5. Broniscer, A. and A. Gajjar, Supratentorial High Grade Astrocitomas and Difusse Brain Stem Glioma: Two Challenges for the Pediatric Oncologist. . Oncologist, 2004. 9(2): p. 197-206. 6. Packer, R.J., Childhood brain tumors: accomplishments and ongoing challenges. J Child Neurol, 2008. 23(10): p. 1122-7. 7. Packer, R.J., Progress and challenges in childhood brain tumors. J Neurooncol, 2005. 75(3): p. 239-42. 8. MacDonald, T.J., D. Aguilera, and C.M. Kramm, Treatment of high-grade glioma in children and adolescents. Neuro Oncol, 2011. 9. Lam, C., E. Bouffet, and U. Bartels, Nimotuzumab in pediatric glioma. Future Oncol, 2009. 5(9): p. 1349-61. 10. Schmidt-Ullrich, R.K., et al., ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene, 2003. 22(37): p. 5855-65. 11. Mendelsohn, J., J. Baselga, and Status of Epidermal Growth Factor Receptor Antagonist in the Biology and treatment of Cancer. . J Clin Oncol 2003. 21 p. 2787-2799. 12. Koul, D., et al., Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther, 2005. 4(11): p. 1681-8. 13. Mateo, C., et al., Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology, 1997. 3(1): p. 71-81. 14. Nimotuzumab drug marketed approval 2011 19/03/2010 [cited 2002 19/02/02]; Available from: http://www.cecmed.sld.cu/Pages/RegSan.htm. 15. Crombet, T., et al., Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother, 2003. 26(2): p. 139-48. 16. Diaz Miqueli, A., et al., Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt), 2007. 26(6): p. 423-31. 17. Perez, R., et al., EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers Journal 2011. 3: p. 2014-2031. 18. Winquist, E., et al., A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). J Clin Oncol, 2002. 21(abstr 926).(21). 19. Crombet, T., et al., Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol, 2004. 22(9): p. 1646-54. 20. Ramakrishnan, M.S., et al., Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs, 2009. 1(1): p. 41-8. 21. Soehartati G, et al., Nimotuzumab combined with radiotherapy reduces primary tumor and nodal volume in advanced undifferentiated nasopharyngeal carcinoma. Asia Pac J Clin Oncol, 2009. 5(3): p. 175-80. 22. Babu, K., et al., An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study. J Clin Oncol 2010. 28(15, abtract 5530): p. 428s. 23. Basavaraj, C., et al., Nimotuzumab with chemoradiation confers survival advantage in treatment naive head and neck tumors overexpressing EGFR. Cancer Biol Ther, 2010. 10(7). 24. Rodriguez, M.O., et al., Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther, 2010. 9(5): p. 343-9. 25. Rojo, F., et al., Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res, 2010. 16(8): p. 2474-82. 26. Crombet, T., et al., Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: preliminary results from a phase II study Eur. J. Cancer Suppl. , 2009. 7 ( 497, abstract ). 27. F. Bach and M. Westphal, Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma. J Clin Oncol 2011. 29(suppl; abstr 2059 ). 28. Crombet, T., et al., Use the humanized anti-EGFR MAb (nimotuzumab) and radiotherapy for the treatment of high grade glioma patients European Journal of Cancer, suppl. , 2008 6(12): p. 168 (abstract No. 530). 29. Ramos, T.C., et al., Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther, 2006. 5(4): p. 375-9. 30. Saurez, G., et al., Clinical Experience with Nimotuzumab in Cuban Pediatric Patients with Brain Tumors, 2005 to 2007. MEDICC Review 2009. 11( No 3): p. 27-33. 31. Fleischhack, G., et al., Final results of a phase III study consisting of nimotuzumab and concomitant standard radiotherapy for the treatment of newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer 2009. Suppl.(abtract O.153): p. 755. 32. Zhao, K.L., et al., A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. Invest New Drugs, 2011. 33. Ling, Y., et al., A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma. J Thorac Dis, 2012. 4(1): p. 58-62. 34. Ramos-Suzarte, M., et al., Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther, 2012. 13(8): p. 600-5. 35. Strumberg, D., et al., Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs, 2010. 36. Bebb, G., et al., Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol, 2011. 67(4): p. 837-45. 37. Choi, H.J., et al., A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer, 2011. 71(1): p. 55-9. 38. Solomon, M.T., et al., Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients. J Clin Oncol 2012. 30(suppl; abstr 2515). 39. Piedra, P. and O. Morejón, Report of the Fifth Nimotuzumab Global Meeting. Biotecnología Aplicada 2010. 27(1): p. 56-61. 40. Saurez, G., Reporte del Séptimo encuentro científico internacional: Nimo–meeting 2012 en la sesión de tumores cerebrales. . Rev Cubana Neurol Neurocir. , 2012. 2(2): p. 5 41. Massimino, M., et al., Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther, 2011. 11(2): p. 247-56. 42. Trotti, A., et al., CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 2003. 13(3): p. 176-81.